Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.60 |
| ▸ | EGFR | P00533 | 7/20 | 0.60 |
| ▸ | CSF1R | P07333 | 3/20 | 0.55 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | HCK | P08631 | 1/20 | 0.53 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078756 | 1.00 | BRAF (0.60) | BRAFEGFRCSF1RKITHCK | |
| SCHEMBL10077601 | 0.92 | BRAF (0.59) | BRAFEGFRCSF1RKITHCK | |
| SCHEMBL2679275 | 0.92 | BRAF (0.59) | BRAFEGFRCSF1RKITHCK | |
| SCHEMBL10078221 | 0.92 | BRAF (0.59) | BRAFEGFRCSF1RKITHCK | |
| SCHEMBL2679132 | 0.92 | BRAF (0.59) | BRAFEGFRCSF1RKITHCK | |
| SCHEMBL2679876 | 0.88 | KIT (0.56) | BRAFEGFRCSF1RKITABL1 | |
| SCHEMBL2679875 | 0.84 | KIT (0.53) | BRAFEGFRCSF1RKIT | |
| SCHEMBL10077224 | 0.84 | KIT (0.53) | BRAFEGFRCSF1RKIT | |
| SCHEMBL27927515 | 0.84 | BRAF (0.48) | BRAFEGFRCSF1RKITHCK | |
| SCHEMBL10054826 | 0.84 | BRAF (0.56) | BRAFEGFRCSF1RKITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | claimed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | claimed |
| US-8426446-B2 | Acrylamide derivative and use thereof in manufacture of medicament | BEIJING SHIQIAO BIOPHARM CO. LTD. (CN) | 2013-04-23 | — | — | US | disclosed |
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | BEIJING JIASHILIANBO PHARM SCI & TECH CO. LTD | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116075-A1 | Acrylamide Derivative And Use Thereof In Manufacture Of Medicament | ABL1, ABL2, BCR | BRAF 21/4885EGFR 40/4885CSF1R 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.